A 68-year-old man with heart failure with reduced ejection fraction (LVEF 30%) is clinically euvolaemic. He is on maximally tolerated doses of an angiotensin receptor-neprilysin inhibitor, a guideline-recommended beta-blocker and a mineralocorticoid receptor antagonist. He has type 2 diabetes and an eGFR of 48 mL/min/1.73 m². Which additional therapy is recommended by the CCS/CHFS heart failure guideline to further reduce hospitalisation and mortality?